Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Capital Expenditures (2021 - 2025)

Senti Biosciences has reported Capital Expenditures over the past 5 years, most recently at $26000.0 for Q2 2025.

  • Quarterly results put Capital Expenditures at $26000.0 for Q2 2025, up 73.33% from a year ago — trailing twelve months through Dec 2025 was $196000.0 (up 653.85% YoY), and the annual figure for FY2025 was $196000.0, up 653.85%.
  • Capital Expenditures for Q2 2025 was $26000.0 at Senti Biosciences, down from $170000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for SNTI hit a ceiling of $7.4 million in Q1 2022 and a floor of -$10.2 million in Q3 2023.
  • Median Capital Expenditures over the past 5 years was $417500.0 (2021), compared with a mean of $885857.1.
  • Peak annual rise in Capital Expenditures hit 172.12% in 2023, while the deepest fall reached 405.87% in 2023.
  • Senti Biosciences' Capital Expenditures stood at $3.3 million in 2021, then crashed by 76.31% to $793000.0 in 2022, then tumbled by 98.49% to $12000.0 in 2023, then decreased by 8.33% to $11000.0 in 2024, then skyrocketed by 136.36% to $26000.0 in 2025.
  • The last three reported values for Capital Expenditures were $26000.0 (Q2 2025), $170000.0 (Q1 2025), and $11000.0 (Q4 2024) per Business Quant data.